There's no blanket restriction on alcohol use, but your prescribing clinician will review your health history
Perjeta (pertuzumab) Disease area(s): Oncology Manufacturer(s): Roche 2024 Sales (USD): $4.11 billion Why it sold so well: Roches Perjeta generated global sales of CHF 3.62 billion ($4.11 billion) last year, maintaining its position as a key therapy in HER2-positive breast cancer
These include individuals with severe kidney disease, acute pancreatitis history, type 1 diabetes, severe diabetic ketoacidosis risk, or active eating disorders
At the starting dose of 0.25mg per week, a single 5mg vial lasts 20 weeks, which is nearly five months
When GLP-1 Therapy Stops Working Most patients on GLP-1 therapy experience a predictable trajectory: rapid initial weight reduction followed by a gradual slowing of progress
A commissioning value is better for fleet management